Skip to content
Screener

Bausch Health Companies BHC Cash & Equivalents

Cash & Equivalents at other companies

Bausch + Lomb logo
Bausch + LombBLCO
$378M+39.0%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$20.42B+9.9%
Staar Surgical logo
Staar SurgicalSTAA
$131.86M-23.8%
Apyx Medical Corporation logo
Apyx Medical CorporationAPYX
$31.14M+0.4%
Ardelyx logo
ArdelyxARDX
$97.19M+7.9%
Ironwood Pharmaceuticals logo
Ironwood PharmaceuticalsIRWD
$79.13M-14.8%

Other financials

Income statement

See full
Revenue$2.5B+11.7%
Operating income-$950.0M-444%
Net income-$1.4B-2,353%
EPS (diluted)-$3.82-2,287%

Balance sheet

See full
Total debt$20.8B-3.5%
Total equity-$2.1B-74.0%
Total assets$24.5B-7.3%

Cash flow

See full
Operating cash flow$230.0M+9.0%
CapEx$109.0M-5.2%
Free cash flow$121.0M+26.0%

Valuation

See full
Market cap$2.21B+3.8%
Enterprise value$21.66B-2.1%
P/S0.2×0.0×

Profitability

See full
Gross margin71.4%
Operating margin5.6%-10.3pp
Net margin-1.9%-0.9pp
FCF margin9.8%-2.8pp

Returns & leverage

See full
Return on equity-70.1%
Debt / equity45.2×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Bausch Health Companies in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The source filing: Bausch Health Companies’s 10-Q, filed April 30, 2026.

Filed
Apr 29, 2026, 6:12 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000885590-26-000053
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Net cash used in financing activities(100)(146)
Effect of exchange rate changes on cash, cash equivalents and restricted cash(4)21
Net decrease in cash, cash equivalents and restricted cash(13)(44)
Cash, cash equivalents and restricted cash, beginning of period1,3251,201
Cash, cash equivalents and restricted cash, end of period$1,312$1,157
Cash and cash equivalents$1,299$1,134
Restricted cash1323
Cash, cash equivalents and restricted cash, end of period$1,312$1,157

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Bausch Health Companies's cash & equivalents?
Bausch Health Companies (BHC) reported cash & equivalents of $1.31B in Q1 2026.
How has Bausch Health Companies's cash & equivalents changed year-over-year?
Bausch Health Companies's cash & equivalents increased by 13.4% year-over-year, from $1.16B to $1.31B.
What is the long-term trend for Bausch Health Companies's cash & equivalents?
Over 5 years (2020 to 2025), Bausch Health Companies's cash & equivalents has grown at a 17.0% compound annual growth rate (CAGR), from $605M to $1.33B.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Bausch Health Companies's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude